18 results about "Scopolamine" patented technology

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of drugs for improving sleep disorder and treating mood disorder or cognitive disorder. The invention provides a traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in parts by mass: 20-30 parts of lycium ruthenicum, 30-40 parts of nitraria fruit, 15-25 parts of gastrodia elata, 13-25 parts of hyperforin perforatum and 2-6 parts of lycopene. The traditional Chinese medicine composition provided by the invention is prepared from lycium ruthenicum, nitraria fruit, gastrodia elata, hyperforin perforatum and lycopene according to a specific ratio, and the composition can effectively relieve anxiety behaviors of chronic stress bound anxiety model mice through ways of resisting oxidation and inflammation, regulating expression of neurotransmitters and the like, prolong sleep time and improve sleep quality. The learning ability and the memory ability of cognitive impairment mice induced by scopolamine are improved, and the neuron density of brain tissues is increased, so that the neuroprotective effect is achieved.

The present invention relates to a composition for preventing, ameliorating or treating central nervous system diseases, comprising a peptidomimetic compound (NIP001) containing hydrophilic arginine and a hydrophobic histidine derivative. In the present invention, the peptidomimetic compound comprising hydrophilic arginine and a hydrophobic histidine derivative was confirmed to effectively inhibit inflammatory responses in microglia and to have the effect of improving the cognitive function of mice with scopolamine-induced cognitive impairment, and thus can be used as a targeted therapeutic agent for central nervous system diseases.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a traditional Chinese medicine composition in the preparation of drugs for improving cognitive impairment. By weight, the traditional Chinese medicine composition comprises: 225-300 parts rhubarb, 50-75 parts pig bile powder, 90-120 parts aster, 360-480 parts scrophularia, 180-240 parts immature bitter orange peel, and 180-240 parts areca nut. This invention is the first to demonstrate that a composition of six traditional Chinese medicines, including scrophularia, rhubarb, and areca nut, significantly improves memory acquisition (induced by scopolamine), consolidation (induced by sodium nitrite), and retrieval impairments, covering the entire process of memory formation, encoding, storage, and retrieval, thus overcoming the limitations of existing drugs that only target a single memory stage.

The present invention discloses a composition for improving cognitive function using a single or complex extract of Acanthopanax koreanum, Astragalus membranaceus, and / or Momordica charantia. The composition increases, in an in-vitro efficacy test, the cell viability of SH-SY5Y cells, which are human-derived neuroblastomas treated with scopolamine that is an oxidative stress-inducing drug, increases the expression of an apoptosis inhibition-related biomarker (Bcl-2), an autophagy-enhancing biomarker (Beclin-1), and an acetylcholine biosynthesis-related enzyme (ChAT), which are neurotransmitters, also increases the expression of the antioxidant-related biomarker HO-1, and increases the inactivation of GSK-3β, which is a therapeutic target for Alzheimer's disease, and furthermore, even in an in-vivo efficacy test, increases the expression of Bcl-2, Beclin-1, ChAT, and HO-1 in the hippocampus and cerebrum of an animal model with reduced cognitive function and memory induced by administration of scopolamine, and inhibits the expression of iNOS, which is an enzyme involved in NO biosynthesis that induces tissue damage.

The invention belongs to the technical field of natural medicines and pharmacology, and particularly relates to a raspberry extract as well as a preparation method and application thereof. Aiming at the problems of brain fatigue and functional hypomnesia caused by high-intensity brainwork of middle-aged and young people below 50 years old in the modern society, the invention provides a preparation process of a targeted enriched active monomer, which comprises the following steps: by taking dried raspberry fruits as a raw material, firstly, carrying out reflux degreasing with n-hexane to remove fat-soluble impurities; and sequentially extracting the degreased filter residues step by step by using ethanol with different concentrations, combining extracting solutions, and concentrating and drying to obtain the traditional Chinese medicine composition. The extract obtained by the preparation process can remarkably improve dysmnesia induced by scopolamine and inhibit the activity of acetylcholin esterase, is suitable for preparing products for relieving mental fatigue and improving learning efficiency, and does not relate to treatment of degenerative diseases such as senile dementia.

This invention relates to a small molecule compound composition and its applications, belonging to the field of biotechnology. The small molecule compound composition of this invention includes NU7441, GW9662, and D609, or their stereoisomers. This invention is the first to discover that this small molecule compound combination can effectively inhibit oxidative damage to corneal epithelial cells caused by hyperosmolarity and significantly improve the survival rate of corneal epithelial cells. In vivo animal experiments show that, compared with the control group, the experimental group of mice injected with scopolamine-induced dry eye model mice, given eye drops containing the small molecule compound combination, showed significantly reduced corneal defects and increased tear secretion. The small molecule compound combination can effectively prevent corneal epithelial damage, has high efficacy, and no obvious drug toxicity. This small molecule compound combination may become a potent and effective drug for the clinical treatment of dry eye in the future.

This invention discloses the application of overexpression of transcription factor AbbHLH29 in improving the biological traits of belladonna. By overexpressing AbbHLH29 in belladonna, this invention increases the expression level of the H6H gene, iron content, chlorophyll a content, aboveground biomass, or the content of scopolamine and anisodamine. The nucleotide sequence of AbbHLH29 is shown in SEQ ID No. 11. This research is not only significant in elucidating the molecular mechanism by which AbbHLH29 regulates the biosynthesis of belladonna alkaloids and iron homeostasis, but also provides important technical support for future research on belladonna alkaloid metabolic engineering.

The invention provides a construction method of a rat xerophthalmia model, which utilizes scopolamine hydrobromide and 1% atropine sulfate ophthalmic gel to jointly induce xerophthalmia so as to induce comprehensive symptoms of rat xerophthalmia. After scopolamine hydrobromide is subcutaneously injected into a rat and atropine ophthalmic gel is dropwise added to eyes of the rat, difference appears in tear secretion, tear film rupture time and cornea staining detection from the second week, the symptom stability can last for more than one month, and obvious difference also exists in pathological examination of an anatomical end point and a TUNEL test. Hypodermic injection of scopolamine hydrobromide can inhibit parsympathetic nerve excitation so as to inhibit gland secretion, so that lacrimal secretion is insufficient; and meanwhile, the atropine ophthalmic gel can inhibit parasympathetic nerves, so that the threshold value of tear secretion is increased, and the tear secretion is reduced. The xerophthalmia model has the advantages that the modeling time is short, the modeling process is not limited by environment temperature and humidity, and model animals after modeling have small individual differences and high symptom specificity.

The application discloses a kind of drug composition for treating pseudomyopia and preparation method thereof, belong to the field of medicine.The application provides the method that scopolamine is combined with tometilcaine in the preparation of the drug for treating pseudomyopia.A kind of drug composition for treating pseudomyopia is also provided.The scopolamine tometilcaine compound eye drops of the application, active ingredients are extracted from plants and crystallized into salt, prepared into compound eye drops, curative effect is remarkable, side effect is low, process is simple, cost is low, medication, carrying, storage is convenient.

The application discloses a potent non-sleepy antiemetic and anti-motion sickness pharmaceutical composition and application thereof, and belongs to the technical field of medicines.The composition comprises five active ingredients of pheniramine maleate, caffeine, vitamin B6, scopolamine and lidocaine.Through the synergistic effect of the components, the composition can strongly inhibit the dizziness and vomiting reaction caused by the vestibular stimulation, and meanwhile, the sedative effect of the antihistamine drug is antagonized by caffeine, so that the side effect of sleepiness of the traditional anti-motion sickness drug is avoided while the anti-motion effect is ensured.Experiments show that the effect of the composition in an anti-motion sickness animal model is obviously better than that of each single drug and a conventional positive control drug.The composition can be used for preparing various pharmaceutical preparations for preventing and treating motion sicknesses such as car sickness, ship sickness and aircraft sickness, and has important clinical application value.

The invention discloses a phenyllactic acid UDP-glycosyl transferase mutant and application thereof, and belongs to the technical field of biological medicine, the phenyllactic acid UDP-glycosyl transferase mutant PLA-UGT-M5 with improved catalytic efficiency is obtained through a directed evolution method, the mutant simultaneously contains five amino acid substitutions F19S, G21E, N128S, I209L and I292V, metabolites are detected in yeast cells, and the activity of the metabolites is improved. The catalytic efficiency is obviously higher than that of a wild type. Further functional verification shows that the PLA-UGT-M5 can remarkably promote biosynthesis of the scopolamine and the scopolamine in a yeast cell factory and a belladonna hairy root system, has a good metabolic engineering application prospect, provides a key tool for efficient biosynthesis of the scopolamine and the scopolamine, and has important industrial application potential.

The invention discloses a closed-loop transcranial stimulation system and a closed-loop transcranial stimulation method. 0.3 mg of scopolamine and 3 mg of midazolam are intramuscularly injected before an operation; after a patient enters a room, sufentanil is subjected to intravenous injection induced by right subclavian vein and radial artery puncture general anesthesia, propofol is subjected to target-control infusion, the plasma target concentration is 3.0 mu g / mL, vecuronium bromide is 0.15 mg / kg, tracheal intubation is performed after 5 min, general anesthesia maintains target-control infusion of propofol, and after the patient enters the room, the target-control infusion of propofol is performed. A TMS stimulation coil electricity-magnetism-heat-stress model, a single-phase and double-phase pulse discharge circuit model and a neuron dynamic response model under the action of a TMS are established, and the influence of TMS system parameters on space-time distribution characteristics of an intracranial induced electric field and neuron membrane potential can be accurately expressed. Behavior perception and system auditory stimulation are combined to be applied to nursing intervention of severe craniocerebral injury coma patients, self-repairing and consciousness awakening of the brain functions of the patients can be effectively promoted, and meanwhile recovery of limb functions and daily life ability of the patients is facilitated.

This invention discloses the application of necrotizing 1 (Necrostatin-1) in the preparation of drugs for the prevention and / or treatment of dry eye, relating to the field of biomedical technology. The application of necrotizing 1 in the preparation of drugs for the prevention and / or treatment of dry eye is described. This invention is the first to discover the application of the programmed necrosis inhibitor Necrostatin-1 in the treatment of dry eye. Nec-1, by inhibiting programmed necrosis, can effectively protect corneal epithelial cells and reduce ocular surface inflammation and damage. In a scopolamine-induced dry eye model, subconjunctival injection of 0.3 μM Nec-1 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, without significant drug toxicity. Nec-1 provides a new targeting strategy for dry eye treatment and may become a potent and effective drug for the clinical treatment of dry eye in the future.

The invention discloses a method for researching a mild cognitive impairment action mechanism of a cornu cervi pantotrichum polypeptide based on a Wnt / beta-catenin signal channel, relates to the technical field of mechanism analysis, and solves the problem of difficulty in realizing spanning from basic research to clinical transformation in the prior art. Randomly dividing the rats into five groups of blank control, model, positive control and VAP high / low dose, continuously performing intragastric administration on each group for 18 days, and feeding distilled water into the blank and model groups; 2 mg / kg scopolamine is injected into abdominal cavities of the model group after 18 days and 2 hours, and normal saline is injected into the blank group; the scopolamine model is used for measuring the 2min static / motion time of the rat by using an open field experiment, and the unilateral common carotid artery ligation model is used for measuring the escape latency / platform penetration times by using a water maze; the method comprises the following steps: taking blood, separating a hippocampal region, and carrying out HE dyeing, ELISA and Western blot; sPSS 21.0 analysis and single factor variance analysis are used for evaluating the difference and Plt; 0.05 or Plt; 0.01 has statistical significance.

This application relates to the field of medicinal chemistry, specifically to a derivative of ligustilide-7-aminocarbamate-4'-substituted aminopropyl ether, its preparation method, and its application. Addressing the shortcomings of ligustilide in AD treatment, this application utilizes previous studies to demonstrate strong eeAChE and huACh inhibitory activity, strong inhibition of self-induction, and Cu... 2+ Induced Aβ 1‑42 Aggregation activity, significantly reduced Aβ 25‑35 The lead compound, scutellarin aglycone-4′-L-amino acid carbamate, which induces tau hyperphosphorylation and significantly improves learning and memory impairment in scopolamine-induced AD model mice, is used to introduce histamine H at the 7-position of its structure. 3 By using the key structural fragment (3-methylpiperidinyl) or cycloheptane group of the receptor antagonist, a cholinesterase inhibitor and histamine H2 receptor antagonist can be obtained. 3 Multi-targeted ligand derivatives with better anti-AD properties through receptor antagonistic synergistic mechanism.

This invention provides a scopolamine-soluble press-fit acupoint patch, its preparation method, and its application. The patch includes: a fixing sheet; an adhesive sheet adhered to one side of the fixing sheet for attaching to human skin, the adhesive sheet having perforations; and a needle body comprising a fixedly connected base and a needle shaft, the base being bonded between the adhesive sheet and the fixing sheet, the needle shaft extending outward through the perforations to penetrate the stratum corneum of the skin to deliver the drug and simultaneously stimulate acupoints. At least one needle shaft is loaded with scopolamine. The fixing sheet connects to the adhesive sheet, thereby fixing the base. Compared to traditional soluble microneedle arrays, the soluble press-fit needles in this acupoint patch significantly extend the needle length, enhancing the acupoint stimulation efficacy, while achieving controlled drug release through a soluble matrix. Experiments show that this acupoint patch exhibits good behavioral improvement effects in treating a motion sickness model.

The invention discloses a pharmaceutical composition for treating pseudomyopia and a preparation method thereof, and belongs to the field of medicines. The invention provides a method for jointly using scopolamine and tropicamide in preparation of a medicine for treating pseudomyopia. The invention also provides a pharmaceutical composition for treating pseudomyopia. According to the scopolamine and tropicamide compound eye drops, active ingredients are extracted from plants and then crystallized into salt, the compound eye drops are prepared, the curative effect is remarkable, the side effect is low, the process is simple, the cost is low, and medication, carrying and storage are convenient.

The invention discloses an application of a scopolamine model in an acetylcholin esterase inhibitor, and relates to the technical field of medicines.The application comprises the steps that S1, the learning memory of the scopolamine model is improved through a compound; s2, the inhibition effect of the compound on acetylcholin esterase is verified, and the compound is specifically (5S)-1-(3, 4-dihydroxyphenyl)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl) heptyl-3-ketone. A plurality of groups of experiments are designed to prove that the compound can remarkably improve the learning and memory dysfunction of AD model mice induced by scopolamine and has dose dependence, an enzyme activity inhibition experiment shows that the compound has strong inhibitory activity on AChE, the half inhibitory concentration (IC50) of the compound reaches 5.5 nM and is more remarkable than that of a clinical first-line anti-AD drug donepezil (IC50 = 12.2 nM), and the compound can be applied to preparation of anti-AD drugs. As the AChE activity increase is a key factor of cholinergic system injury in the AD pathological process, the compound is speculated to reduce hydrolysis of acetylcholine by inhibiting the AChE activity, and further improve the learning and memory ability of model animals.